HALO (Halozyme Therapeutics) Insider Ownership: 9.93 % (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
90 GF Score
Price $106.92
GF Value $99.38
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Insider Ownership?

Halozyme Therapeutics HALO -0.94% 90 Insider Ownership is 9.93 % as of Sep. 15, 2026. GuruFocus rates HALO with a GF Score™ of 90/100 and a GF Value™ of $99.38 (Fairly Valued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Halozyme Therapeutics's insider ownership is 9.93%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Halozyme Therapeutics's Institutional Ownership is 110.14%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Halozyme Therapeutics's Float Percentage Of Total Shares Outstanding is 76.29%.

Halozyme Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Insider Ownership Chart

Halozyme Therapeutics Historical Data

The historical data trend for Halozyme Therapeutics can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Insider Ownership 9.37 9.36 9.87 9.79 9.80 9.84 9.81 9.81 9.51 9.93
HALO
90GF Score
Halozyme Therapeutics Inc HALO
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 9.93 % mean?
Halozyme Therapeutics (HALO) has a Insider Ownership of 9.93 % as of Sep. 15, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Insider Ownership too high?
Halozyme Therapeutics' current Insider Ownership is 9.93 %. Overall, Halozyme Therapeutics has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Insider Ownership compare to ARWR and CORT?
Halozyme Therapeutics' Insider Ownership of 9.93 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Insider Ownership is 9.93 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $99.38, compared to a current price of $106.92 — trading 7.6% above its estimated fair value. The current Insider Ownership is 9.93 %. Halozyme Therapeutics' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Insider Ownership is 9.93 % as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of $106.92 is trading 7.6% above its estimated GF Value™ of $99.38. GuruFocus considers Halozyme Therapeutics to be Fairly Valued.

Key valuation signals for HALO:

  • Insider Ownership: 9.93 %
  • GF Value™: $99.38 vs. price of $106.92 (7.6% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
90GF Score

Get the complete analysis for HALO

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$106.92
Price
$99.38
GF Value